<prompt> role of toclizumab in a patient with ARDS developed due to covid 19it acts by halting lysogenic phase of corona virusit stops the lung parenchymal damge by the virusit is a IL-6 receptor inhibitorall the above  <response>: Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab exposure and hospital-related moality among patients requiring intensive care unit ICU suppo for COVID-19. ref : 